World
Oxford Vaccine Shows Early Promise But Market Is Unconvinced
- Astra shares give up earlier gains on caution over prospects
- Vaccine increased levels of antibodies and T-cells in study
This article is for subscribers only.
A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, and is now set to move into larger trials that are likely to be decisive on how effective they truly are.
The results weren’t enough to convince the market, however. AstraZeneca Plc fell from a record high in New York trading on concerns over whether its vaccine can match the progress seen in programs from Pfizer Inc. and BioNtech SE, as well as Moderna Inc.